The Sydney Children's Hospital experience with the oral iron chelator deferiprone (L1)

Transfusion Science

Volumn 23, Issue 3, 2000, Pages 239-240

  Berdoukas, Vasili ^a   Bohane, Tim ^a   Eagle, Craig ^b   Lindeman, Rob ^c   DeSilva, Keshani ^c   Tobias, Vivienne ^c   Painter, Dorothy ^b   Fraser, Ian ^c  

^a SYDNEY CHILDREN'S HOSPITAL   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; IRON; IRON CHELATING AGENT;

ANEMIA; BLOOD TRANSFUSION; CLINICAL ARTICLE; CONFERENCE PAPER; DRUG HYPERSENSITIVITY; HEPATITIS C; HUMAN; HUMAN TISSUE; IRON CHELATION; IRON OVERLOAD; JOINT EFFUSION; LIVER FIBROSIS; LIVER INJURY; PATIENT MONITORING;

AUSTRALIA; BLOOD TRANSFUSION; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; PYRIDONES; TREATMENT OUTCOME;

EID: 0033693910     PISSN: 09553886     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-3886(00)00092-8     Document Type: Conference Paper

References (3)

1. Iron-chelation therapy with oral deferiprone in patients with thalassemia major
2. Results of long-term deferiprone (L1) therapy: A report by the International Study Group on Oral Iron Chelators
3. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for Thalassaemia Major